Advertisements
Feeds:
Posts
Comments

Search Results for 'CRISPR'


CRISPR Based Research Awarded NHGRI Grants, The University of California, Berkeley’s Doudna will receive $2.1 million and The Broad Institute’s Zhang will receive $1.1 million Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 10/10/2017 Gene Editing Market: CRISPR/CAS9 to be the fastest-growing technology segment – 2024 Request for Sample Copy of this Report @ http://bit.ly/2wExTM9 Rising […]

Read Full Post »


Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing Reporter: Aviva Lev-Ari, PhD, RN [Boldface added] Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and […]

Read Full Post »


Innovations on the CRISPR System for Gene Editing: (1) Cryo-electron microscopy-based visualization of Cas3 Enzyme Cleavage (2) New tool testing an entire genome against a CRISPR molecule to predict potential errors and interactions Curator and Reporter: Aviva Lev-Ari, PhD, RN   Boom in human gene editing as 20 CRISPR trials gear up A pioneering CRISPR […]

Read Full Post »


Doudna and Charpentierand their teams to receive wide-ranging patents in many countries:  European Patent Office (EPO) and UK Intellectual Property Office – broad patent for CRISPR-Cas9 gene-editing technology to the University of California and the University of Vienna Reporter: Aviva Lev-Ari, PhD, RN   The EPO patent will cover the single-guide CRISPR-Cas9 technology in cells of […]

Read Full Post »


Gene Editing Consortium of Biotech Companies: CRISPR Therapeutics $CRSP, Intellia Therapeutics $NTLA, Caribou Biosciences, ERS Genomics, UC, Berkeley (Doudna’s IP) and University of Vienna (Charpentier’s IP), is appealing the decision ruled that there was no interference between the two sides, to the U.S. Court of Appeals for the Federal Circuit, targeting patents from The Broad Institute. […]

Read Full Post »


CRISPR Patent Battle Determined on 2/15/2017 – USPTO issues a verdict in legal tussle over rights to genome-editing technology Curator: Aviva Lev-Ari, PhD, RN Broad Institute prevails in heated dispute over CRISPR patents Sharon Begley sharon.begley@statnews.com @sxbegle In a one-sentence judgment by the Patent Trial and Appeal Board, the three judges decided that there is “no […]

Read Full Post »


Top 50 Women in CRISPR : Women in CRISPR, Legal Status of Inventions and Declaration of the Heroes in CRISPR Curator: Aviva Lev-Ari, PhD, RN   Part 1: Top 50 Women in CRISPR : Women in CRISPR  See List, below SOURCE https://docs.google.com/spreadsheets/u/1/d/10sOQkAg_IKkqozJXqdewiGi6-88W1gnfq5D3g-m22Og/htmlview Part 2: UPDATED – Status “Interference — Initial memorandum” – CRISPR/Cas9 – The […]

Read Full Post »


CRISPR Therapeutics raises a $56M IPO, but patent battles, potential stock drops loom by Ben Adams | Oct 19, 2016 3:52am And then there were three: After Editas ($EDIT) and Intellia ($NTLA) went public this year, CRISPR has brought up the rear with its IPO. But the biotech will need to gear up for a […]

Read Full Post »


“CRISPR-Cas9, bring me a gene,  Encoding for a specific protein: Three words: CRISPR. A Capella Reporter: Aviva Lev-Ari, PhD, RN AROUND FLG Hi Marc , A couple of serious ethical issues have arisen in the genetics news this week. First, a new study has revealed that two major clinical genomic databases show major racial bias towards […]

Read Full Post »


FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing by news.wiley.com Reporter: Aviva Lev-Ari, PhD, RN   FEBS Journal Special Issue on CRISPR FEBS Journal Special Issue on CRISPR/Cas9 The FEBS Journal The discovery of CRISPR in archaea and bacteria The FEBS Journal Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens The FEBS Journal […]

Read Full Post »

Next »